Ni J, Wan CG, Sui ZQ. Efficacy and safety of radiotherapy in patients with microsatellite stable or proficient mismatch repair colorectal cancer liver metastasis. World J Gastrointest Oncol 2025; 17(3): 102873 [DOI: 10.4251/wjgo.v17.i3.102873]
Corresponding Author of This Article
Zi-Qi Sui, Department of Gastroenterology, The Second Affiliated Hospital of Zhejiang Chinese Medical University, No. 88 Jiefang Road, Hangzhou 310005, Zhejiang Province, China. ziqisui@163.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Case Control Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Oncol. Mar 15, 2025; 17(3): 102873 Published online Mar 15, 2025. doi: 10.4251/wjgo.v17.i3.102873
Efficacy and safety of radiotherapy in patients with microsatellite stable or proficient mismatch repair colorectal cancer liver metastasis
Jie Ni, Chu-Gen Wan, Zi-Qi Sui
Jie Ni, Chu-Gen Wan, Department of Gastroenterology, The First People’s Hospital of Linping District, Hangzhou 311100, Zhejiang Province, China
Zi-Qi Sui, Department of Gastroenterology, The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou 310005, Zhejiang Province, China
Author contributions: Ni J designed the research study; Wan CG performed the research; Sui ZQ performed the experiments and analyzed the data; and all authors contributed to editorial changes, and read and approved the final manuscript.
Institutional review board statement: This study was approved by the ethics committee of The Second Affiliated Hospital of Zhejiang Chinese Medical University.
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Data sharing statement: No additional data are available.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Zi-Qi Sui, Department of Gastroenterology, The Second Affiliated Hospital of Zhejiang Chinese Medical University, No. 88 Jiefang Road, Hangzhou 310005, Zhejiang Province, China. ziqisui@163.com
Received: November 1, 2024 Revised: December 5, 2024 Accepted: January 14, 2025 Published online: March 15, 2025 Processing time: 106 Days and 0.2 Hours
Core Tip
Core Tip: This study investigates the efficacy and safety of a combined therapy involving radiotherapy, immune checkpoint inhibitors, and tyrosine kinase inhibitors in patients with colorectal cancer liver metastasis characterized by microsatellite stability or proficient mismatch repair, who traditionally show limited response to immune checkpoint inhibitors alone. The combination approach aims to leverage the potential of radiotherapy and tyrosine kinase inhibitors to modify the tumor microenvironment, improve antigen presentation, and boost immune activation, offering a new therapeutic strategy to improve disease control rates without increasing the risk of adverse effects. This study provides valuable insights into optimizing treatment regimens for microsatellite stability/proficient mismatch repair colorectal cancer liver metastasis patients.
